ANTITUMOR ACTIVITY OF QUINOCARMYCIN AGAINST CARCINOMA OF THE LUNG IN HUMAN TUMOR CLONOGENIC ASSAY

Search this Article

Author(s)

    • CHIANG CHIDER
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • KANAZAWA FUMIHIKO
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • MATSUSHIMA YUKA
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • NAKANO HIDEHIKO
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • NAKAGAWA KAZUHIKO
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • TAKAHASHI HIDENOBU
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • TERADA MASAAKI
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • MORINAGA SHOJIRO
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • TSUCHIYA RYOSUKE
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • SASAKI YASUTSUNA
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung
    • SAIJO NAGAHIRO
    • Pharmacology:Pathology Division, National Cancer Center Research Institute:Surgery Division:Department of Internal Medicine, National Cancer Center Hospital:Division of Pulmonary Medicine, Department of Internal Medicine, Veterans General Hospital-Taichung

Abstract

Quinocarmycin monocitrate is a novel antitumor antibiotic isolated from Streptomyces melanovinaceus. We have utilized a human tumor clonogenic assay to test the antitumor activity of this drug against carcinoma of the lung and to compare its activity with those of mitomycin C or cisplatin, which are components of the clinically effective regimens in therapy for this desease. The overall in vitro response rate (defined as less than 50% survival of tumor colony forming units) for quinocarmycin at 0.1 and 1.0 μg/ml continuous exposure was 42% and 72%, respectively, which was superior to that of other drugs. Quinocarmycin and other antitumor drugs do not have identical spectra of antitumor activities in vitro, suggesting that this compound with good in vitro activity should be further developed for clinical trials.

Journal

  • Journal of pharmacobio-dynamics

    Journal of pharmacobio-dynamics 10(9), 431-435, 1987-09

    The Pharmaceutical Society of Japan

Codes

  • NII Article ID (NAID)
    110003654975
  • NII NACSIS-CAT ID (NCID)
    AA00704585
  • Text Lang
    ENG
  • ISSN
    0386846X
  • Data Source
    NII-ELS 
Page Top